20192019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Cristina Sonetto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M. T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S. C., Maltese, G. & Scambia, G., Dec 2019, In : Gynecologic Oncology. 155, 3, p. 406-412 7 p.

Research output: Contribution to journalArticle

  • Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

    Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M. T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S. C., Maltese, G. & Scambia, G., Dec 2019, In : Gynecologic Oncology. 155, 3, p. 406-412 7 p.

    Research output: Contribution to journalArticle

  • Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial: Gynecologic Oncology

    Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M. T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S. C., Maltese, G. & Scambia, G., 2019, In : Gynecol. Oncol.. 155, 3, p. 406-412 7 p.

    Research output: Contribution to journalArticle

  • RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy

    Bogani, G., Matteucci, L., Tamberi, S., Ditto, A., Sabatucci, I., Murgia, F., Arcangeli, V., Maltese, G., Comerci, G., Stefanetti, M., Sonetto, C., Calareso, G., Marchiano, A., Chiappa, V., Lorusso, D. & Raspagliesi, F., Jun 2019, In : European Journal of Obstetrics and Gynecology and Reproductive Biology. 237, p. 93-99 7 p.

    Research output: Contribution to journalArticle